If you have been reading about REV-ERB and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
=== Low-profile chains === Low-profile chains are chains with low teeth and safety elements between teeth. These chains are used on consumer and small professional saws for non-experienced operators. These chains are more insensitive against dirt, but require more frequent sharpening.
=== Border controls and traffic restrictions === Switzerland temporarily reintroduced controls at the border with France from 10 to 19 June 2026. The Federal Council stated that although the summit would take place in France, Geneva, Lausanne and the wider Lake Geneva region were exposed to security risks connected with the event. In the canton of Geneva, only seven road border crossings with France remained open from 12 to 18 June 2026: Anières, Moillesulaz, Thônex-Vallard, Bardonnex, Perly, Meyrin and Ferney-Voltaire. Crossings through railway stations and Geneva Airport remained authorised, but other crossings, including for cyclists and pedestrians, were restricted. Geneva authorities also warned of disruption to public transport, road traffic, as well as temporary restrictions affecting some public spaces. A priority access sticker system, known as a macaron, was introduced for eligible essential workers and residents. Geneva authorities stated that access to Switzerland remained possible without one, subject to controls and available crossings. Additional traffic restrictions were introduced on the Geneva motorway network, including restrictions on the A1 motorway between Geneva Airport and the Bardonnex customs crossing during the summit period.
Medical imaging is also central in supplying the biometric data necessary to establish baseline features of anatomy and physiology so as to increase the accuracy with which early or fine-detail abnormalities are detected. These diagnostic techniques are often performed in combination with general pathology procedures and are themselves often essential to developing new understanding of the pathogenesis of a given disease and tracking the progress of disease in specific medical cases. Examples of important subdivisions in medical imaging include radiology (which uses the imaging technologies of X-ray radiography) magnetic resonance imaging, medical ultrasonography (or ultrasound), endoscopy, elastography, tactile imaging, thermography, medical photography, nuclear medicine and functional imaging techniques such as positron emission tomography. Though they do not strictly relay images, readings from diagnostics tests involving electroencephalography, magnetoencephalography, and electrocardiography often give hints as to the state and function of certain tissues in the brain and heart respectively.
Robert 'Bob' Ramage FRS (4 October 1935 — 16 October 2019) was an organic chemist, born in Glasgow, who specialised in the synthesis and biosynthesis of natural products, peptides, and proteins. Following his undergraduate degree in chemistry and the University of Glasgow, he stayed on for a PhD in organic chemistry. After his time at Glasgow, he followed his interest in natural products synthesis to Harvard and then Basel, before taking up a lectureship in organic chemistry at the University of Liverpool where his attention was drawn to peptides. His peptide synthesis research continued at the University of Manchester Institute of Science and Technology (UMIST), where he also served as head of department. He returned to Scotland in 1984, taking up the Forbes chair of organic chemistry at the University of Edinburgh, where he remained until retirement in 2000. Outside of academia, in 1994 he founded the company Albachem, which utilised his work with peptides. He was elected Fellow of the Royal Society of Chemistry (1977), Royal Society of Edinburgh (1986), and the Royal Society (1992).
Sources: en.wikipedia.org
=== Phase 1 === Dexmedetomidine (BXCL-501; Igalmi; KalmPen) – α2-adrenergic receptor agonist [21] ENX-205 – dopamine D2 and D3 receptor antagonist and serotonin 5-HT1A and 5-HT2A receptor agonist [22] (R)-Midomafetamine ((R)-MDMA; EMP-01) – serotonin–norepinephrine releasing agent, weak serotonin 5-HT2 receptor agonist, and entactogen [23] Mirodenafil (AR-1001) – phosphodiesterase PDE5 inhibitor [24]
Similarly to the SIR model, also, in this case, we have a Disease-Free-Equilibrium (N,0,0,0) and an Endemic Equilibrium EE, and one can show that, independently from biologically meaningful initial conditions
Police issue a "Gang Conflict Warrant" in Levin following a spate of local gang violence and shootings. 22 August – Dairy cooperative Fonterra sells its Mainland, Anchor brands, and processing operations in Australia and Sri Lanka to French dairy company Lactalis for NZ$3.845 billion. 23 August — NZ Post suspends several postal services to the United States and its unincorporated territories in response to the Trump Administration's new 15 percent tariff rates. 25 August – The murder trial of a man accused of perpetrating the Loafers Lodge fire in May 2023, which claimed five lives, commences at the Wellington High Court. 27 August — Economic Growth Minister Nicola Willis announces that the Government would amend legislation with the goal of breaking the country's supermarket duopoly. 28 August: Associate Justice Minister Nicole McKee announces the Government will amend alcohol legislation to make it harder for people to block liquor licenses and to introduce one-off special trading hours for pubs and clubs hosting major sport and cultural events. NZ Post introduces a new business parcel service to the United States in response to the Trump Administration's 15 percent tariff rate. 160 Stuff journalists affiliated with the E tū union strike in Auckland, Hamilton, Wellington and Christchurch to protest work and pay conditions. 29 August — Neil Quigley resigns as chairman of the Reserve Bank of New Zealand's board.
Sources: en.wikipedia.org
Wharton's jelly (Latin: substantia gelatinea funiculi umbilicalis) is a gelatinous substance within the umbilical cord, largely made up of mucopolysaccharides (hyaluronic acid and chondroitin sulfate). It acts as a mucous connective tissue containing some fibroblasts and macrophages, and is derived from extra-embryonic mesoderm of the connecting stalk.
=== 2021–present: Post-breakup activity and abandoned fourteenth studio album === The 2021 retirement of King Crimson's "Seven-Headed Beast" line-up, and Fripp's subsequent statement that the band had finished, left a certain amount of written/performed King Crimson music unrecorded in the studio, although some of that material had appeared on live recordings from the time. New original songs performed in concert by the band had included "Meltdown", "Radical Action", "Radical Action II", "The Errors", and more. Versions of two Fripp/Jakszyk songs originally intended for King Crimson ("Uncertain Times" and "Separation") had also emerged on Jakszyk's 2020 solo album Secrets and Lies, with participation from Fripp, Harrison, Levin and Collins. Following the most recent retirement of the band, Jakko Jakszyk hinted, suggested and ultimately stated that this material will see formal release as a studio album, the band's first in over twenty years since the release of The Power to Believe. In August 2021, Jakszyk referred to the existence of "about forty to fifty minutes' worth of new (King Crimson) stuff, a number of songs I've co-written with Robert and some instrumental things he's written.
According to data from 2024, the 250 seats in the People's Council are distributed as follows: Sunni Muslims (171 seats), reflecting their majority status in Syria's population, Alawites (39 seats), corresponding to their demographic proportion, Christians (23 seats), allocated across various provinces, Druze (9 seats), with a significant number from the Suwayda Governorate, Shia Muslims (5 seats), Ismailis (2 seats) and Murshidites (1 seat). Out of a 210-member People's Assembly formed after the fall of the Ba'athist government in 2024, 140 seats were allocated through a transitional electoral process. Of those elected, six were women and 10 were minority representatives (Kurds, Christians, and two Alawites). The 70 appointed members included 15 women, with officials stating the appointments were intended to address limited representation in the elected portion of the assembly.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.